1. , , , . Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 2009;15: 627–631.
2. , , , et al. Early onset multiple sclerosis: A longitudinal study. Neurology 2002;59:1006–1010.
3. , , , et al. Multiple sclerosis in childhood: Clinical features of 149 cases. Mult Scler 1997;3:43–46.
4. , , , . Early onset MS under the age of 16: Clinical and paraclinical features. Acta Neurol Scand 1992;86:280–284.
5. , , , et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009;72:232–239.
6. , , , et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322–1329.
7. , , , , , . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–285.
8. , , , , , . Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
9. , , , et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705–2712.
10. , , , et al. Primary extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type in the CNS. Neuropathology 2001;21:174–180.
11. , , , , , . Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006;116:3183–3194.
12. , , , et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128:988–1002.
13. , , , , , . Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. Am J Neuroradiol 2002;23:267–272.
14. , , , et al. Clinicopathological review: Tumefactive demyelination in a 12-year-old girl. Neurosurgery 2005;56:1051–1057.
15. , Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: Review of the literature and treatment proposal. J Child Neurol 2009;24:431–437.
16. , , . Pediatric tumefactive demyelination: Case series and review of the literature. Pediatr Neurol 2002;26:18–25.
17. , , , , , . A case of pediatric tumefactive demyelinating lesion misdiagnosed and treated as glioblastoma. J Child Neurol 2008;23:944–947.
18. , , , . An uncommon illness with a rare presentation: Neurosurgical management of ADEM with tumefactive demyelination in children. Childs Nerv Syst 2010;26:655–661.
19. , , , . Acute disseminated encephalomyelitis. Neurology 2007;68(16 Suppl 2):S23–36.
20. , , , et al. Clinical features and viral serologies in children with multiple sclerosis: A multinational observational study. Lancet Neurol 2007;6:773–781.
21. , , , et al. Perivenous demyelination: Association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010;133(Pt 2):333–348.
22. , , , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–846.
23. , , , et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol 2005;62:865–870.
24. , , , et al. Isolated demyelinating syndromes: Comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001;7:359–363.
25. , , , et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002;8:115–118.
26. , , , .Multiple sclerosis in children under 6 years of age. Neurology 1999;53:478–484.
27. , , , . CSF characteristics in early-onset multiple sclerosis. Neurology 2004;63:1966–1967.
28. , , , , , . Multiple sclerosis in childhood: Report of 15 cases. Brain Dev 1991;13:410–416.
29. . The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children. Acta Neurol Scand 1989;80:425–431.
30. , , , et al. Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: A single centre prospective study. Mult Scler 2009;15:363–370.
31. , , , et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010;74:399–405.
32. , , , , , . Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123:2407–2422.
33. , , , , , . Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001;56:1308–1312.
34. , , . Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients. Neurology 2002;59:1224–1231.
35. , , , et al. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for multiple sclerosis and disability. J Pediatr 2004;144:246–252.
36. . The immunology of multiple sclerosis. Semin Neurol 2008;28:29–45.
37. , . Insights into thymic aging and regeneration. Immunol Rev 2005;205:72–93.
38. , , , et al. CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: Implications for T cell memory. Mech Ageing Dev 1996;86:173–195.
39. , , , , , . Age-related impaired proliferation of peripheral blood mononuclear cells is associated with an increase in both IL-10 and IL-12. Exp Gerontol 1999;34:243–252.
40. . Changes in the B-cell repertoire with age. Vaccine 2000;18:1624–1628.
41. . Age-dependent alterations of the T cell repertoire and functional diversity of T cells of the aged. Immunol Res 2006;36:221–228.
42. , , . Aging and T-cell diversity. Exp Gerontol 2007;42:400–406.
43. , , . Altered lymphocyte recognition repertoire during ageing. III. Changes in MHC restriction patterns in parental T lymphocytes and diminution in T suppressor function. Immunology 1984;52:611–620.
44. , , , et al. Variation rhythms of lymphocyte subsets during healthy aging. Neuroimmunomodulation 2008;15:365–379.
45. , , . The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age. J Leukoc Biol 2008;84:1454–1461.
46. . The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:43–72.
47. , , . Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:11–26.
48. , . Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol 2003;112:837–849; quiz 850.
49. , , . Multiple sclerosis and regulatory T cells. J Clin Immunol 2008;28:697–706.
50. , , , et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008;63:98–111.
51. , . Myelin basic protein and myelin oligodendrocyte glycoprotein T-cell repertoire in childhood and juvenile multiple sclerosis. Mult Scler 2006;12:412–420.
52. , . Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res 2003;28:223–239.
53. , , , , . Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599–603.
54. , , , , , . Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102:671–678.
55. , , , , , . Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations?Acta Neurol Scand 1988;78:318–323.
56. , , , et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500–508.
57. , , , et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101–104.
58. , , , et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008;196:124–132.
59. , , , et al. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 2008;44:22–25.
60. , , , et al. The blood–brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008;131:785–799.
61. , , , et al. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173–1175.
62. , , , . Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971–979.
63. , , , , , . Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 1995;2:249–252.
64. , , , , . Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28– suppressor cell. Ann Neurol 1991;30:42–47.
65. , , , et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995;154:2959–2968.
66. , , , , , . Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 2000;165:1641–1651.
67. , , , , . Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98:70–77.
68. , . Do myelin-directed antibodies predict multiple sclerosis?N Engl J Med 2003;349:107–109.
69. , , . Multiple sclerosis – The plaque and its pathogenesis. N Engl J Med 2006;354:942–955.
70. , , , et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009;65:639–649.
71. , , , et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003;136:140–148.
72. , , , et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211–217.
73. , , . B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001;112:1–14.
74. , . Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment. J Neuroimmunol 2006;180:3–8.
75. , , . The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007;32:251–256.
76. , , , et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
77. , , , , . Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180:63–70.
78. , , , et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092–6099.
79. , , , , , . B lymphocytes are required for development and treatment of autoimmune diseases. Ann NY Acad Sci 2005;1050:19–33.
80. , , , , , . Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology 2006;26:162–167.
81. , . Epidemiology of multiple sclerosis. In Principles of Neuroepidemiology, ed. and . St Louis, MO:Butterworh Heinemann, 2001.
82. , . Migrant studies in multiple sclerosis. Prog Neurobiol 1995;47:425–448.
83. , , , , . Epstein–Barr virus in pediatric multiple sclerosis. JAMA 2004;291:1875–1879.
84. , . Epidemiology of multiple sclerosis: From risk factors to prevention. Semin Neurol 2008;28:17–28.
85. , , , , , . Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008;71:1033–1035.
86. , , , et al. High seroprevalence of Epstein–Barr virus in children with multiple sclerosis. Neurology 2006;67:2063–2065.
87. , , , et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 2003;327:316.
88. , , , , . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832–2838.
89. , , . 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861–7864.
90. , , , , , . Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol 2003;105:438–448.
91. , , , et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 2000;30:498–508.
92. , . The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002;408:200–204.
93. , . CD8(+) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 2002;99:5557–5560.
94. , , , . Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 2001;119:16–29.
95. , , . 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2000;103:171–179.
96. , , , , , . 1,25-dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 1996;55:904–914.
97. , . Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005;175:4119–4126.
98. , , , et al. 1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007;178:145–153.
99. , , , et al. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol 2004;89–90:437–441.
100. , . 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405–2411.
101. , , , , , . Dendritic cell modulation by 1alpha,25-dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:6800–6805.
102. , , . Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995;15:5789–5799.
103. , . 1,25-dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc 1996;1:68–71.
104. , , , . 1,25-dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 2006;83:1299–1309.
105. , , , . The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007;103:558–562.
106. , . 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000;11:221–229.
107. , , , , . Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007;103:416–419.
108. , , , . 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 2007; 85:2480–2490.
109. , , , , , . Prevention of murine experimental allergic encephalomyelitis: Cooperative effects of cyclosporine and 1 alpha, 2 5-(OH)2D3. J Neuroimmunol 1995;61:151–160.
110. , , . Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. Med Hypotheses 1986;21:193–200.
111. , , , , . A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294–1296.
112. , , , , , . Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 2000;177:65–71.
113. , , , et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet 2005;19:25–38.
114. , , , et al. Susceptibility and outcome in MS: Associations with polymorphisms in pigmentation-related genes. Neurology 2004;62:2323–2325.
115. , , , et al. Past environmental sun exposure and risk of multiple sclerosis: A role for the Cdx-2 vitamin D receptor variant in this interaction. Mult Scler 2009;15:563–570.
116. , , , et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5:e1000369.
117. , , . Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32–41.
118. , , . Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. Am J Neuroradiol 2007;28:1843–1849.
119. , , , et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 2005;20:822–825.